Early cancer pill trial halted after testing on 29 patients
NCT ID NCT06232408
Summary
This was an early safety study for a new oral cancer drug called RP-1664. It tested the drug in 29 people with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see how the drug behaved in the body, but the trial was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Participating Site 1004
New York, New York, 10065, United States
-
Participating Site 1008
New York, New York, 10032, United States
-
Participating Site 1012
New Haven, Connecticut, 06519, United States
-
Participating Site 1025
San Francisco, California, 94143, United States
-
Participating Site 4001
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.